Importantly, AD co-pathology has a decisive impact on plasma GFAP levels in ALS patients; thus, plasma GFAP represents an accurate biomarker for detecting AD co-pathology in ALS, which may influence the cognitive phenotype [181]. This evidence concerns the gene GFAP and Alzheimer disease.